Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia

Journal of Nutrition

Volumn 136, Issue 4, 2006, Pages 987-991

  Jonkers, Iris J A M ^a   Smelt, Augustinus H M ^a   Princen, Hans M G ^b   Kuipers, Folkert ^c   Romijn, Johannes A ^a   Boverhof, Renze ^c   Masclee, Ad A M ^a   Stellaard, Frans ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bezafibrate; Bile acid synthesis; Fish oil; Hypertriglyceridemia; Triglycerides

Indexed keywords

BEZAFIBRATE; CHENODEOXYCHOLIC ACID; FISH OIL; LATHOSTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BODY MASS; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; GALLSTONE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 33645500213     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.4.987     Document Type: Article

References (50)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-9.
2. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19:783-91.
3. Einarsson K, Hellstrom K, Kallner M. Gallbladder disease in hyperlipoproteinaemia. Lancet. 1975;1:484-7.
4. Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B. Prevalence of gallbladder disease in hyperlipoproteinemia. Dig Dis Sci. 1979;24:459-64.
5. Asplund-Carlson A, Lund E, Björkhem I, Carlson LA. Studies in hypertriglyceridaemia VI: serum lathosterol concentration is raised in hypertriglyceridaemic non-diabetic males with hyperinsulinaemia. J Intern Med. 1999;245:247-52.
6. Shoda J, Miyamoto J, Kano M, Ikegami I, Matsuzaki Y, Tanaka N, Osuga T, Miyazaki H. Simultaneous determination of plasma mevalonate and 7-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia: Convenient indices for estimating hepatic defects of cholesterol and bile acid syntheses and biliary cholesterol supersaturation. Hepatology. 1997;25:18-26.
7. Ahlberg J, Angelin B, Bjorkhem I, Einarsson K, Leijd B. Hepatic cholesterol metabolism in normo- and hyperlipidemic patients with cholesterol gallstones. J Lipid Res. 1979;20:107-15.
8. Beil U, Grundy SM, Crouse JR, Zech L. Triglyceride and cholesterol metabolism in primary hypertriglyceridemia. Arteriosclerosis. 1982;2:44-57.
9. Einarsson K, Hellstrom K, Kallner M. Bile acid kinetics in relation to sex, serum lipids, body weights and gallbladder disease in patients with various types of hyperlipoproteinemia. J Clin Invest. 1974;54:1301-11.
10. Angelin B, Hershon KS, Brunzell JD. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proc Natl Acad Sci USA. 1987;84:5434-8.
11. Angelin B, Einarrson K. Hellstrom, K. & Leijd, B. Bile acid kinetics in relation to endogenous triglyceride metabolism in various types of hyperlipoproteinemia. J Lipid Res. 1978;19:1004-16.
12. Duane WC. Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res. 1995;36:96-107.
13. Nestel PJ, Hunter JD. Differences in bile acid excretion in subjects with hypercholesterolaemia, hypertrglyceridaemia and overweight. Aust N Z J Med. 1974;4:497-501.
14. Duane WC, Hartich LA, Bartman AE, Ho SB. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res. 2000;41:1384-9.
15. Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B. Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology. 1980;79:90-4.
16. Fruchart JC, Brewer HBJ, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol. 1998;81:912-7.
17. Cooper J, Geizerova H, Oliver MF. Clofibrate and gallstones. Lancet. 1975;1:1083.
18. Bateson MC, Maclean D, Ross PE, Bouchier IA. Clofibrate therapy and gallstone induction. Am J Dig Dis. 1978;23:623-8.
19. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
20. Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am J Med. 1987;83:37-43.
21. Bertolotti M, Concari M. Loria, P., Abate, N., Pinetti, A., Guicciardi, M. E. & Carulli, N. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rate of cholesterol 7 alpha-hydroxylation in humans. Arterioscler Thromb Vasc Biol. 1995;15:1064-9.
22. Stahlberg D, Reihner E, Rudling M, Bergland L, Einarsson K, Angelin B. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase. Hepatology. 1995;21:1025-30.
23. Nestel PJ. Fish oil and cardiovascular disease: lipids and arterial function. Am J Clin Nutr. 2000;71: suppl:228S-231S.
24. Bucher HC, Heugstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med. 2002;112:298-304.
25. Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, et al. Gallbladder dysmotility: a risk factor for gallstone formation in hypertriglyceridemia. Reversal upon triglyceride-lowering therapy by both bezafibrate and fish-oil. Gut. 2003;52:109-15.
26. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on DetectionEvaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23.
27. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002;112:275-80.
28. Kempen HJM, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-55.
29. Hulzebos CV, Renfurm L, Bandsma RH, Verkade HJ, Boer T, Boverhof R, Tanaka H, Mierau I, Sauer PJ, et al. Measurement of parameters of cholic acid kinetics in plasma using a microscalestable isotope dilution technique: application to rodents and humans. J Lipid Res. 2001;42:1923-9.
30. Berr F, Stellaard F, Pratschke E, Paumgartner G. Effects of cholecystectomy on the kinetics of primary and secondary bile acids. J Clin Invest. 1989;83:1541-50.
31. Duane WC. Cholesterol metabolism in familial hypertriglyceridemia: effects of obesity versus triglyceride levels. J Lab Clin Med. 1997;130:635-42.
32. Stahlberg D, Rudling M, Angelin B, Bjorkhem I, Forsell P, Nilsell K, Einarsson K. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997;25:1447-50.
33. Miettinen TA. Cholesterol production in obesity. Circulation. 1971;44:842-50.
34. Leijd B. The effect of weight reduction on biliary lipid metabolism in patients with hyperlipoproteinemia type IV. Metabolism. 1981;30:1185-9.
35. Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7 alpha-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21:1840-5.
36. Guo Q, Wang PR, Milot DP, Ippolito MC, Hernandez M, Burton CA, Wright SD, Chao YS. Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim Biophys Acta. 2001;1533:220-32.
37. Sirtori CR, Paoletti R, Mancini M, Crepaldi G, Manzato E, Rivellese A, Pamparana F, Stragliotto E. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr. 1997;65:1874-81.
38. Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study. Diabetes Care. 1997;20:913-21.
39. Bravo E, Cantafora A, DeLuca V, Tripodi M, Avella M, Botham KM. The mechanism underlying the hypocholesterolemic effect of chronic fish oil feeding in rats is not due to increased excretion of dietary cholesterol. Atherosclerosis. 1998;139:253-263.
40. Smit MJ, Verkade HJ, Havinga R, Vonk RJ, Scherphoff GL. In 't Veld, G. & Kuipers, F. Dietary fish oil potentiates bile acid-induced cholesterol secretion into bile in rats. J Lipid Res. 1994;35:301-10.
41. Smit MJ, Temmerman AM, Wolters H, Kuipers F, Beynen AC, Vonk RJJ. Dietary fish oil-induced changes in intrahepatic cholesterol transport and bile acid synthesis in rats. J Clin Invest. 1991;88:943-51.
42. Berr F, Goetz A, Schreiber E, Paumgartner G. Effect of dietary n-3 versus n-6 polyunsaturated fatty acids on hepatic excretion of cholesterol in the hamster. J Lipid Res. 1993;34:1275-84.
43. Cheema SK. Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7 alpha-hydroxylase gene expression. J Lipid Res. 1997;38:315-23.
44. Horton JD, Cuthbert JA, Spady DK. Regulation of hepatic 7α-hydroxylase expression and response to dietary cholesterol in the rat and hamster. J Biol Chem. 1995;270:5381-7.
45. Adler RD, Bennion LJ, Duane WC, Grundy SM. Effects of low dose chenodeoxycholic acid feeding on biliary lipid metabolism. Gastroenterology. 1975;68:326-34.
46. Einarsson K, Ericsson S, Ewerth S, Reihner E, Rudling M, Stahlberg D, Angelin B. Bile acid sequestrants: mechanism of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40: suppl1:S53-8.
47. Miller NE, Nestel PJ. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet. 1974;2:929-31.
48. Angelin B, Einarrson K, Hellstrom K, Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res. 1978;19:1017-24.
49. Dallongeville J, Bauge E, Tailleux A, Peters JM, Gonzales FJ. Fruchart. j. C. & Staels, B. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem. 2001;276:4634-9.
50. Fisher EA, Pan M, Chen X, Wu X, Wang H, Jamil H, Sparks JD, Williams KJ. The triple threat to nascent apolipoprotein B. J Biol Chem. 2001;276:27855-63.